



ASX Announcement

23 February 2026

Atomo H1 FY26 Results Presentation

Atomo Diagnostics Limited (ASX:AT1) is pleased to announce that it will release its H1 FY26 Results on Thursday, 26 February 2026.

A results briefing webinar for analysts and investors, hosted by Managing Director & CEO, John Kelly and Financial Controller, Suzy Elhlou, will be held on Thursday, 26 February 2026 at 2pm (AEDT).

To access the webinar please pre-register via [this link](#):

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement. This platform offers an opportunity to submit questions and share comments. To access Atomo's Investor Hub please scan the QR code or visit <https://investors.atomodiagnostics.com/auth/signup>



~ ENDS ~

For more information, please contact:

John Kelly
Managing Director & CEO
e. john.kelly@atomodiagnostics.com
p. +61 401 922 279

Investor Queries
investorqueries@atomodiagnostics.com

This announcement was authorised by the Managing Director & CEO.

About Atomo

Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health. See more at www.atomodiagnostics.com